Loading stock data…
NEUP
$5.22-0.05 (-0.95%)
Pre-Market$5.25+0.03 (+0.57%)· Last close May 1
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neuphoria Therapeutics Inc. in the Healthcare sector is trading at $5.22. The stock is currently near its 52-week low of $3.65, remaining 21.6% below its 200-day moving average. Technical signals show overbought RSI of 75 and bullish MACD crossover, explaining why NEUP maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 75) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.22
Potential Upside
5%
Whystock Fair Value$5.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$26.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.62%
Volume
Today's trading volume
17,757
Recent News
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?
Key Insights Neuphoria Therapeutics' estimated fair value is US$3.34 based on 2 Stage Free Cash Flow to Equity...
BC-Most Active Stocks
td class="col-issue">New Era Energy & Digital Inc.
Neuphoria scraps social anxiety hopeful after Phase III miss
Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes that BNC210 may have hope in PTSD.
Investors Parse Earnings Reports With US Equity Futures Flat Tuesday Pre-Bell
US stock futures were little changed in Tuesday's premarket session as investors parsed pre-market e